MARKET

MGEN

MGEN

Miragen Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.71
-0.03
-0.18%
Opening 10:52 12/02 EST
OPEN
16.74
PREV CLOSE
16.74
HIGH
16.74
LOW
16.48
VOLUME
8.14K
TURNOVER
--
52 WEEK HIGH
34.05
52 WEEK LOW
4.665
MARKET CAP
65.35M
P/E (TTM)
-1.5714
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mid-Afternoon Market Update: Nasdaq Turns Positive; Cinedigm Shares Slide
Toward the end of trading Tuesday, the Dow traded down 0.30% to 29,861.95 while the NASDAQ rose 0.21% to 11,948.77. The S&P also fell, dropping 0.12% to 3,622.50.
Benzinga · 11/17 19:46
KNDI, RIOT, IBIO and GDRX among midday movers
Gainers: Phoenix Tree (DNK) +65%.Lexicon Pharmaceuticals (LXRX) +43%.Riot Blockchain (RIOT) +40%.Zomedica Pharmaceuticals (ZOM) +33%.Miragen Therapeutics (MGEN) +28%.AXT (AXTI) +27%.Glory Star New Media Group (GSMG) +26%.Yunhong CTI (CTIB) +23%.Kandi Technologies (KNDI) +22%.Sequential Brands (SQBG)
Seekingalpha · 11/17 17:44
Mid-Day Market Update: Sequential Brands Gains After Q3 Results; Brainstorm Cell Therapeutics Shares Plunge
Midway through trading Tuesday, the Dow traded down 0.45% to 29,814.37 while the NASDAQ fell 0.05% to 11,918.36. The S&P also fell, dropping 0.29% to 3,616.42.
Benzinga · 11/17 17:37
Lexicon Pharmaceuticals, Zomedica Pharmaceuticals leads healthcare gainers; Brainstorm Cell Therapeutics, GoodRx Holdings among losers
Gainers: Lexicon Pharmaceuticals (LXRX) +45%, Zomedica Pharmaceuticals (ZOM) +33%, Miragen Therapeutics (MGEN) +17%, SQZ Biotechnologies (SQZ) +15%, PLx Pharma (PLXP) +13%.Losers: Brainstorm Cell Therapeutics (BCLI) -67%, GoodRx Holdings (GDRX) -19%, iBio (IBIO) -18%, Co-Diagnostics (CODX) -17%, Alterity Therapeutics (ATHE) -16%.
Seekingalpha · 11/17 16:06
Microcaps mostly among midday movers
Gainers: Urovant Sciences Ltd. (UROV) +94%.CBAK Energy Technology, Inc. (CBAT) +68%.Asia Pacific Wire & Cable Corporation Limited (APWC) +63%.National Holdings Corporation (NHLD) +46%.Electrameccanica Vehicles Corp. (SOLO) +35%.Polar Power, Inc. (POLA)
Seekingalpha · 11/13 18:15
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
Zacks · 11/09 13:58
Marvell Technology Group, Credit Suisse Group leads premarket losers' pack
Cancer Genetics (CGIX) -38% after upsized public offering.Tricida (TCDA) -29% after updating its end-of-review Type A meeting with the FDA.Miragen Therapeutics (MGEN) -15%.Nokia (NOK) -16% after Q3 earnings results.CPS Technologies (CPSH) -14% after Q3 earnings results.Blue Apron
Seekingalpha · 10/29 12:33
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.; No Terms Disclosed
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED) Company plans to use private placement financing proceeds of $91 million to advance
Benzinga · 10/28 11:17
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MGEN. Analyze the recent business situations of Miragen Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MGEN stock price target is 40.00 with a high estimate of 75.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 3.87M
% Owned: 98.97%
Shares Outstanding: 3.91M
TypeInstitutionsShares
Increased
6
38.25K
New
15
-13.17K
Decreased
3
32.98K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.27%
Pharmaceuticals & Medical Research
+0.61%
Key Executives
Chairman/Independent Director
Jeffrey Hatfield
President/Chief Operating Officer
Jonathan Violin
Chief Executive Officer/Director
Lee Rauch
Chief Financial Officer/Chief Accounting Officer/Treasurer/Secretary
Jason Leverone
Other
Diana Escolar
Director
Peter Harwin
Director
Tomas Kiselak
Independent Director
Christopher Bowden
Independent Director
Arlene Morris
Independent Director
Joseph Turner
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MGEN
Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Miragen Therapeutics Inc stock information, including NASDAQ:MGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGEN stock methods without spending real money on the virtual paper trading platform.